Therapy News and Research

RSS

Researchers recommends robotic prostatectomy over traditional open surgery method

While sharp debate continues among medical professionals as to whether a radical prostatectomy performed with the assistance of a robotic device is more beneficial than the traditional open surgery method, research just published by investigators at The Cancer Institute of New Jersey (CINJ) shows new evidence supporting the safety of the robotic procedure - including what is believed to be one of the lowest complication rates to date. CINJ is a Center of Excellence of UMDNJ-Robert Wood Johnson Medical School.

6 Aug 2010

Researchers reprogram human embryonic stem cells to iPS cells for use in regenerative medicine

Human embryonic stem (ES) cells and adult cells reprogrammed to an embryonic stem cell-like state-so-called induced pluripotent stem or iPS cells-exhibit very few differences in their gene expression signatures and are nearly indistinguishable in their chromatin state, according to Whitehead Institute researchers.The pluripotency of ES cells fueled excitement over their use in regenerative medicine. While ethical hurdles associated with the clinical application of human ES cells appeared to have been overcome with the development of methods to create iPS cells, some recent research has suggested that ES and iPS cells have substantial differences in which sets of genes they express.

6 Aug 2010

Dermatologist discusses treatment for acne and melasma

The U.S. Census Bureau predicts that the Asian-American population will total 40 million people by 2050. While as a whole this group is characterized by very dark hair and dark eyes, there is much diversity in Asian skin tones – from very light, pale skin to light or dark brown skin. One common thread is the pigmentation issues that Asian Americans often face as after-effects of other dermatologic problems that can be as troublesome as the original condition itself.

6 Aug 2010

U.S. Physical Therapy net income for second-quarter 2010 increases 23% to $4.5 million

U.S. Physical Therapy, Inc., a national operator of outpatient physical therapy clinics, today reported results for the second quarter and six months ended June 30, 2010.

6 Aug 2010

Scientific findings reveal combination antibiotic therapy effective for ulcerative colitis

The link between Hormone Replacement Therapy and reduced risk of distal large bowel cancer in women; a promising combination antibiotic therapy for ulcerative colitis patients; and the high-rate of alcoholic liver disease mortality, are among the scientific findings featured in the August issue of The American Journal of Gastroenterology.

6 Aug 2010

Studies show biological agents play important role in maintaining remission in Crohn's disease

Biological agents may play an important role in maintaining remission in Crohn's disease, according to two new studies in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association Institute.

6 Aug 2010

Patheon, Dendreon announce signing of technology transfer agreement

Patheon, a global provider of drug development and manufacturing services to the international pharmaceutical industry, announced today that it has signed a technology transfer agreement with Dendreon Corporation for commercial supply of proprietary density gradient solutions required during the PROVENGE (sipuleucel-T) manufacturing process.

6 Aug 2010

Nanosphere reports net loss of $13.8M for second-quarter 2010

Nanosphere, Inc., a leader in the development and commercialization of advanced molecular diagnostics systems, today reported financial results for the second quarter ended June 30, 2010.

6 Aug 2010

WaferGen launches SmartChip System for discovery, validation of biomarkers

WaferGen Biosystems, Inc., a leading developer of state-of-the-art genomic analysis systems, today announced it has launched the breakthrough WaferGen SmartChip Real-Time PCR System, the next-generation Real-Time PCR system for discovery and validation of biomarkers, or gene expression patterns, on a single platform. The SmartChip System is designed to provide accurate, highly sensitive and high-throughput gene expression profiling capabilities to researchers, clinicians and pharmaceutical companies.

6 Aug 2010

Incyte second-quarter total revenues increase to $49.8 million

Incyte Corporation today reported second quarter 2010 financial results and described progress for several of its clinical programs.

5 Aug 2010

Life Technologies, UCSD Moores Cancer Center to use SOLiD 4 technology to study CLL

Life Technologies Corporation and the University of California at San Diego Moores Cancer Center today announced a partnership to use SOLiD 4 genomic analysis technology in a research program to study chronic lymphocytic leukemia, a cancer of the white blood cells. The CLL research is made possible by funding from the National Institutes of Health and will enable scientists to survey the whole transcriptomes of 96 CLL tumor samples for potential biomarkers.

5 Aug 2010

$Aeterna Zentaris announces $1.5M NIH award for AEZS-108 Phase 1/2 study in refractory prostate cancer$

Aeterna Zentaris announces $1.5M NIH award for AEZS-108 Phase 1/2 study in refractory prostate cancer

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that the National Institutes of Health ("NIH") has awarded Dr. Jacek Pinski, Associate Professor of Medicine at the Norris Comprehensive Cancer Center of the University of Southern California, a grant of about US$1.5 million over three years to conduct a Phase 1/2 study in refractory prostate cancer with the Company's doxorubicin LHRH receptor targeted conjugate compound, AEZS-108.

5 Aug 2010

New article highlights importance of patient safety features in design of IV needleless connectors

A new article by infection control expert William Jarvis, M.D., President, Jason and Jarvis Associates, LLC, highlights the importance of patient safety features in the design of IV needleless connectors.

5 Aug 2010

New volume on Growth hormone therapy

Growth hormone (GH) has been used therapeutically for over 50 years. Since the development of a nearly unlimited supply of recombinant human GH in the mid-1980s, children with less severe GH deficiency can also profit from GH replacement therapy.

5 Aug 2010

CEL-SCI produces and fills first lot of Multikine

CEL-SCI Corporation announced today that it has successfully produced and filled its first lot of Multikine® in preparation for the upcoming pivotal Phase III trial targeting advanced primary head and neck cancer.

5 Aug 2010

TCA Cellular Therapy enrolls first patient for adult stem cell clinical trial

TCA Cellular Therapy, LLC has enrolled its first patient to participate in the U.S. Food and Drug Administration (FDA) first adult stem cell clinical trial to treat spinal cord injuries. Enrollee and Marine Veteran, Matt Cole was paralyzed from the chest down in a 2005 insurgent attack in Iraq.

5 Aug 2010

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

Merck reported that two pivotal Phase III registration studies for boceprevir, its investigational oral hepatitis C protease inhibitor, have been completed and met the primary endpoints: in both studies in patients with chronic hepatitis C virus (HCV) genotype 1 infection, the addition of boceprevir to treatment with PEGINTRON® and REBETOL® significantly increased the number of patients who achieved sustained virologic response, compared to control groups that received Peg/riba plus placebo.

5 Aug 2010

Hayfever: time we moved exams to the winter?

Crucial exams take place during adolescence in most societies, which can have a major impact on an individual’s career trajectory. In a Guest Editorial appearing in the August issue of Expert Review of Respiratory Medicine, a team of UK experts review the evidence of the disease burden associated with hayfever and summarize recent evidence suggesting that poorly controlled hayfever can adversely impact on exam performance.

5 Aug 2010

Healing Touch helps to restore normal energy balance

Greenwich Hospital surgical, labor and delivery, and oncology patients are among those who have received a healing boost through a form of energy therapy known as Healing Touch.The hospital, known for its reputation of service excellence, is among a growing number of medical facilities utilizing Healing Touch, which is a gentle, noninvasive therapy shown to facilitate the relaxation response to enhance the healing process. Research shows that, in addition to inducing a deep sense of calm and relaxation, Healing Touch helps to reduce pain, decrease anxiety, promote sleep and improve an overall sense of well-being.

5 Aug 2010

Neurobiologists discover potential cure for degenerative vision diseases

Neurobiologists funded by the Office of Naval Research have discovered a potential cure for degenerative vision diseases leading to terminal blindness.

5 Aug 2010

Therapy News and Research

Researchers recommends robotic prostatectomy over traditional open surgery method

Researchers reprogram human embryonic stem cells to iPS cells for use in regenerative medicine

Dermatologist discusses treatment for acne and melasma

U.S. Physical Therapy net income for second-quarter 2010 increases 23% to $4.5 million

Scientific findings reveal combination antibiotic therapy effective for ulcerative colitis

Studies show biological agents play important role in maintaining remission in Crohn's disease

Patheon, Dendreon announce signing of technology transfer agreement

Nanosphere reports net loss of $13.8M for second-quarter 2010

WaferGen launches SmartChip System for discovery, validation of biomarkers

Incyte second-quarter total revenues increase to $49.8 million

Life Technologies, UCSD Moores Cancer Center to use SOLiD 4 technology to study CLL

Aeterna Zentaris announces $1.5M NIH award for AEZS-108 Phase 1/2 study in refractory prostate cancer

New article highlights importance of patient safety features in design of IV needleless connectors

New volume on Growth hormone therapy

CEL-SCI produces and fills first lot of Multikine

TCA Cellular Therapy enrolls first patient for adult stem cell clinical trial

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

Hayfever: time we moved exams to the winter?

Healing Touch helps to restore normal energy balance

Neurobiologists discover potential cure for degenerative vision diseases

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News